ZAI LAB(09688),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

ZAI LAB(09688)

12.800-0.860-6.30%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

Company Profile
Company Name
ZAI LAB
Market
SEHK
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.zailaboratory.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.

1D
5D
Day
Week
Month

High

13.480

Open

13.380

Volume%

0.92

Low

12.400

Close

13.660

T/O Rate

0.36%

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"pagemeta":{"title":"ZAI LAB(09688),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ZAI LAB(09688) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ZAI LAB,09688,ZAI LAB股票,ZAI LAB股票老虎,ZAI LAB股票老虎国际,ZAI LAB行情,ZAI LAB股票行情,ZAI LAB股价,ZAI LAB股市,ZAI LAB股票价格,ZAI LAB股票交易,ZAI LAB股票购买,ZAI LAB股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ZAI LAB(09688),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ZAI LAB(09688) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}},"tab":"community","symbol":"09688","data":{"stockData":{"symbol":"09688","market":"HK","secType":"STK","nameCN":"ZAI LAB","latestPrice":12.8,"timestamp":1714723740033,"preClose":13.66,"halted":0,"volume":3526954,"delay":0,"floatShares":992087430,"shares":992087430,"eps":-2.7051672682385663,"marketStatus":"Not Yet Opened","change":-0.86,"latestTime":"05-03 16:09:00","open":13.38,"high":13.48,"low":12.4,"amount":45143898,"amplitude":0.079063,"askPrice":12.8,"askSize":42200,"bidPrice":12.76,"bidSize":25600,"shortable":3,"etf":0,"ttmEps":-2.7051672682385663,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1714959000000},"marketStatusCode":0,"adr":0,"listingDate":1601222400000,"exchange":"SEHK","adjPreClose":13.66,"openAndCloseTimeList":[[1714699800000,1714708800000],[1714712400000,1714723200000]],"volumeRatio":0.9182235145321993,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"tweetData":{"bottom":false,"list":[{"cardType":"TWEET","cardId":"TWEET.251973141086424","cardData":[{"tweetId":"251973141086424","author":{"authorId":"4103332230805300","name":"Smartkarma Research Network","avatar":"https://community-static.tradeup.com/news/39fffba2ff205c2730b5bf07e3de6647","userType":5,"introduction":"https://on.skr.ma/free4tiger","crmLevel":0,"crmLevelSwitch":0,"individualDisplayBadges":[],"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"[Zai LAB (ZLAB US, SELL, TP US$20) TP Change]: Two Positive News Drove up 2024 Growth Target","digest":"⬇ $Zai Lab Ltd(ZLAB)$ - Positive news for Zai Lab's Efgartigimod as rival drug is withdrawn and it is included in 2024 NDRL, leading to an 8.8% increase in top line but no change in operating loss. TP raised to $20. Continue reading on Smartkarma:- https://www.smartkarma.com/insights/zai-lab-zlab-us-sell-tp-us-20-tp-change-two-positive-news-drove-up-2024-growth-target?utm_source=tiger_community By Eric Wen, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/eric-wen?utm_source=tiger_community On Zai Lab Ltd (ZLAB):- https://www.smartkarma.com/entities/zai-lab-ltd?utm_source=tiger_community","plainDigest":"⬇ $Zai Lab Ltd(ZLAB)$ - Positive news for Zai Lab's Efgartigimod as rival drug is withdrawn and it is included in 2024 NDRL, leading to an 8.8% increase in top line but no change in operating loss. TP raised to $20. Continue reading on Smartkarma:- https://www.smartkarma.com/insights/zai-lab-zlab-us-sell-tp-us-20-tp-change-two-positive-news-drove-up-2024-growth-target?utm_source=tiger_community By Eric Wen, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/eric-wen?utm_source=tiger_community On Zai Lab Ltd (ZLAB):- https://www.smartkarma.com/entities/zai-lab-ltd?utm_source=tiger_community","sourceLanguage":"EN","currentLanguage":"EN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1702548099773,"gmtModify":1702548099815,"symbols":["LU1267930490.SGD","LU1244550221.USD","LU1267930227.SGD","NWS","LAB","LU0310800965.SGD","LU1244550494.USD","LU0823411888.USD","ZLAB","TGT","LU1244550577.SGD","LU0211328371.USD","LU0310799852.SGD","LU0052756011.USD","LU0128525689.USD","LU0211327993.USD","09688"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":53417,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://ttm.financial/post/251973141086424","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":555,"authorId":"4103332230805300"}]}],"size":1,"extra":{"requestId":"f4708b75060747f0af615878f4406b40"}},"newsData":null,"noticeData":{"listData":[],"currentPage":1,"bottom":true},"companyData":{"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":0.0273},{"period":"3month","weight":-0.2711},{"period":"6month","weight":-0.3725},{"period":"1year","weight":-0.5303},{"period":"ytd","weight":-0.4047}],"compareEarnings":[{"period":"1week","weight":0.0467},{"period":"1month","weight":0.1047},{"period":"3month","weight":0.1894},{"period":"6month","weight":0.046},{"period":"1year","weight":-0.0738},{"period":"ytd","weight":0.0838}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.016509},{"month":2,"riseRate":0.5,"avgChangeRate":-0.001648},{"month":3,"riseRate":0,"avgChangeRate":-0.143693},{"month":4,"riseRate":0.75,"avgChangeRate":0.076104},{"month":5,"riseRate":0.25,"avgChangeRate":-0.060959},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.041878},{"month":7,"riseRate":0.666667,"avgChangeRate":0.0492},{"month":8,"riseRate":0.666667,"avgChangeRate":-0.00144},{"month":9,"riseRate":0,"avgChangeRate":-0.186765},{"month":10,"riseRate":0.5,"avgChangeRate":-0.079493},{"month":11,"riseRate":0.75,"avgChangeRate":0.139277},{"month":12,"riseRate":0.5,"avgChangeRate":0.014831}],"exchange":"SEHK","name":"ZAI LAB","nameEN":"ZAI LAB"},"aProfile":null}}}